Medical Condition News

RSS

China Medical Technologies' AUTOMAGLIA 90 analyzer and Down Syndrome Screening receive SFDA approval

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic company, today announced that it received approval for its AUTOMAGLIA 90 fully-automated ECLIA analyzer as well as Down Syndrome screening kit from the State Food and Drug Administration of China.

29 Apr 2010

AVEO Pharmaceuticals reports net loss of $14.4 million for first-quarter 2010

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced financial results for the quarter ended March 31, 2010, provided an update on progress towards achievement of 2010 goals as well as 2010 financial guidance.

29 Apr 2010

Power3 Medical Products to present four abstracts at International Congress of Alzheimer's Disease

Power3 Medical Products, Inc. announced that four abstracts were accepted for presentation to the annual meeting of the International Congress of Alzheimer's Disease on July 12, 2010 in Honolulu, Hawaii. The presentations will cover results from protein biomarker discovery, drug response, test development, and ongoing clinical validation trials of the NuroPro AD biomarkers and blood test for Alzheimer's disease.

29 Apr 2010

Obese children metabolize caffeine and dextromethorphan at different rates than healthy weight children

Researchers from the University of Minnesota College of Pharmacy have provided the first evidence-based data on changes in drug metabolism in obese children as compared to healthy weight children.

29 Apr 2010

87% of people risk dangerous levels of skin damage

Nearly nine out of ten people (87 per cent) could be risking dangerous levels of skin damage, which can lead to skin cancer, because they are either not using the right amount of sunscreen, not sure of the amount they use or are not using any at all - according to a new survey by Superdrug and Cancer Research UK.

29 Apr 2010

Science behind ME

Juliet Chenery-Robson decided to use photography to make people look at Myalgic Encephalopathy in a different light when her 18-year-old daughter Emilia was diagnosed with the illness five years ago.

29 Apr 2010

Nanotechnology for study of individual molecule interaction in live cells

A University of Alberta-led research team has taken a major step forward in understanding how T cells are activated in the course of an immune response by combining nanotechnology and cell biology. T cells are the all important trigger that starts the human body's response to infection.

29 Apr 2010

Genetic test to predict newborns requiring hospital readmission shortly after birth

The results of two separate research studies taking place at Children's Mercy Hospitals and Clinics will help physicians use genetic testing to prevent complications, and ease the worry of new parents by predicting in advance which newborns may require readmission to the hospital shortly after birth. The studies also will help physicians identify which of their young patients are likely to respond well - or not - to steroid therapy for asthma.

29 Apr 2010

Removing unruptured AVM decreases risk of hemorrhaging, provides better outcomes to patients

Individuals diagnosed with a brain arteriovenous malformation, an abnormal tangle of arteries and veins, are at an increased risk of vessel rupture and bleeding that can cause stroke and permanent brain damage.

29 Apr 2010

Cardiac Science responds to FDA communications on AED recall

Cardiac Science Corporation, responded to FDA communications released yesterday related to the AED recall first announced in November, 2009. The Agency communication specifies additional affected models and offers further guidance to users of AEDs affected by potential component defects in some of the Company's AEDs.

29 Apr 2010

Panel finds insufficient evidence to support preventive measures for cognitive decline, Alzheimer's disease

Many preventive measures for cognitive decline and for preventing Alzheimer's disease-mental stimulation, exercise, and a variety of dietary supplements-have been studied over the years. However, an independent panel convened this week by the National Institutes of Health determined that the value of these strategies for delaying the onset and/or reducing the severity of decline or disease hasn't been demonstrated in rigorous studies.

29 Apr 2010

Albireo to present study results of A3309 in patients with chronic constipation at 2010 DDW annual meeting

Albireo today announced that additional clinical data will be reported from a recent study assessing the safety, tolerability and efficacy of A3309 in patients with chronic constipation. A3309 is a first-in-class investigational compound for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC). The results will be presented during the 2010 Digestive Disease Week (DDW) annual meeting being held in New Orleans, US.

29 Apr 2010

Air pollution can damage heart and lead to increased risk of heart disease: Study

A post-mortem study of the hearts of 21 young people in Mexico City has found that the heart begins to show the adverse effects of air pollution at a young age and that tiny bits of inactivated bacteria that hitch a ride on pollutants may make the problem worse.

29 Apr 2010

CINJ trial targets new combination therapy for advanced solid tumors

Building off recent laboratory discoveries relating to how cancer cells become resistant to therapies that attempt to starve cancer, scientists at The Cancer Institute of New Jersey (CINJ) are now applying that knowledge to a process in which cancer cells eat themselves to downsize and resist therapy. The ultimate goal of this effort is to improve upon current anticancer treatments.

29 Apr 2010

Researchers develop lottery game to assess extent of spatial neglect

Patients recovering from stroke sometimes behave as if completely unaware of one half of the world: colliding with obstacles on their left, eating food only from the right side of their plate, or failing to dress their left side. This puzzling phenomenon is termed "spatial neglect" and it affects roughly 45% of patients suffering from a stroke in the right side of the brain.

29 Apr 2010

Most parents restrict playtime activities for asthmatic children

New data released today find that 82 percent of parents of children ages 4-12 with asthma report having restricted playtime activities to help avoid triggers and prevent asthma attacks in their children, with 47% of them keeping children with asthma inside when allergy season is in full swing. Working parents, who more often report experiencing stress related to raising a child with asthma than non-working parents (44% vs. 38%), take more precautions, such as more often swapping carpeting for wood flooring (30% vs. 17%).

29 Apr 2010

Improved management practices can reduce annual costs from diabetes-related complications

Milliman Inc., a premier global consulting and actuarial firm, today released an analysis detailing the economic burden of type 2 diabetes on major healthcare payers and quantifying the savings that could result from better patient management practices.

29 Apr 2010

Astrazeneca settles drug marketing lawsuit, plea deal rejected for possibly defective heart device maker

The New York Times: AstraZeneca has settled a case and agreed to pay $520 million after federal investigations into its marketing practices for a schizophrenia drug, Seroquel. The announcement came Tuesday from Attorney General Eric Holder. Government officials, including Health and Human Services Secretary Kathleen Sebelius, said the company paid illegal kickbacks to doctors to promote drugs for unapproved uses by children, the elderly, veterans and prisoners, which is illegal under federal law.

29 Apr 2010

Pain Therapeutics reports net loss of $1.0 million for first-quarter 2010

Pain Therapeutics, Inc., a biopharmaceutical company, today reported first quarter 2010 financial results. Net loss for Q1 2010 was $1.0 million, or $0.02 per share, compared to a net loss of $1.8 million, or $0.04 per share, for Q1 2009.

29 Apr 2010

OSI Pharmaceuticals announces European Commission's approval of Tarceva for NSCLC

OSI Pharmaceuticals, Inc. announced today that its international partner for Tarceva® (erlotinib), Roche, received approval from the European Commission for Tarceva as a monotherapy maintenance treatment in patients with advanced non-small cell lung cancer (NSCLC) whose disease remains largely unchanged (stable disease) after platinum-based initial chemotherapy.

29 Apr 2010

Medical Condition News

China Medical Technologies' AUTOMAGLIA 90 analyzer and Down Syndrome Screening receive SFDA approval

AVEO Pharmaceuticals reports net loss of $14.4 million for first-quarter 2010

Power3 Medical Products to present four abstracts at International Congress of Alzheimer's Disease

Obese children metabolize caffeine and dextromethorphan at different rates than healthy weight children

87% of people risk dangerous levels of skin damage

Science behind ME

Nanotechnology for study of individual molecule interaction in live cells

Genetic test to predict newborns requiring hospital readmission shortly after birth

Removing unruptured AVM decreases risk of hemorrhaging, provides better outcomes to patients

Cardiac Science responds to FDA communications on AED recall

Panel finds insufficient evidence to support preventive measures for cognitive decline, Alzheimer's disease

Albireo to present study results of A3309 in patients with chronic constipation at 2010 DDW annual meeting

Air pollution can damage heart and lead to increased risk of heart disease: Study

CINJ trial targets new combination therapy for advanced solid tumors

Researchers develop lottery game to assess extent of spatial neglect

Most parents restrict playtime activities for asthmatic children

Improved management practices can reduce annual costs from diabetes-related complications

Astrazeneca settles drug marketing lawsuit, plea deal rejected for possibly defective heart device maker

Pain Therapeutics reports net loss of $1.0 million for first-quarter 2010

OSI Pharmaceuticals announces European Commission's approval of Tarceva for NSCLC

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Latest News